Cargando…
AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer
One of the challenges in prostate cancer (PCa) treatment is lacking biomarkers that could accurately predict PCa progression. The most widely used biomarkers for PCa was prostate-specific antigen (PSA) level. However, PSA testing had low specificity for prostate cancer due to some other kinds of dis...
Autores principales: | Cui, Feilun, Hu, Jiangpeng, Tan, Jian, Tang, Huaming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565543/ http://dx.doi.org/10.21037/tau.2017.s079 |
Ejemplares similares
-
AB078. Knockdown of SPC25 inhibits cell proliferation and cycle progression in prostate cancer
por: Cui, Feilun, et al.
Publicado: (2017) -
AB079. A next generation sequencing parallel biopsy protocol
por: Li, Jing, et al.
Publicado: (2018) -
AB124. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer
por: Zhao, Shancho, et al.
Publicado: (2016) -
AB125. The correlation of SRSF1 and survivin in prostate cancer
por: Xiao, Bangming, et al.
Publicado: (2016) -
AB262. Expression of vasohibin-1 in prostate cancer and its progress research
por: Zhang, Bo, et al.
Publicado: (2016)